Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions for dental and medical professionals, has released its financial results for Q4 and the full year 2024. The company reported total annual sales of $12.7 billion, marking a 2.7% increase from 2023.
Chairman and CEO Stanley M. Bergman highlighted the successful completion of the 2022-2024 BOLD+1 Strategic Plan, which exceeded its goal of generating 40% of operating income from high-growth, high-margin businesses. Looking ahead, Henry Schein has launched the 2025-2027 BOLD+1 Strategic Plan, expecting 2025 to serve as the foundation for long-term earnings growth.
As part of the new strategy, the company has restructured its organization into three segments:
- Global Distribution and Value-Added Services ($10.8 billion in sales)
- Global Specialty Products ($1.4 billion in sales)
- Global Technology ($0.6 billion in sales)
Leadership changes include the appointments of Andrea Albertini to oversee Global Distribution and Technology, and Tom Popeck to lead Global Specialty Products.
In Q4 2024, Henry Schein posted $3.2 billion in revenue, with a 5.8% increase over Q4 2023. Adjusted EBITDA grew to $270 million, reflecting strong financial performance. The company also announced a restructuring plan aimed at generating $75-$100 million in annual cost savings by the end of 2025.
With KKR’s investment, Henry Schein expects high-single to low-double-digit earnings growth in the coming years.
Click here to read the full press release from Henry Schein.
